Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostics and motion preserving technologies, announced today that it has met several major scientific milestones in its development of the first genetic prognostic test for Adolescent Idiopathic Scoliosis and has closed a $6 million tranche of its Series B financing.
Axial Biotech meets major scientific milestones;